Match Document Document Title
US20100076017 SITAMAQUINE TOSYLATE FOR THE TREATMENT OF LEISHMANIASIS  
Disclosed in a novel compound of formula (IA) and its use in the treatment of leishmaniasis infections.
US20150148318 METHOD FOR INHIBITING GROWTH OF CANCER CELLS  
A method of inhibiting the growth of cancer cells is disclosed in which cancer cells that contain an enhanced amount relative to non-cancerous cells of one or more of phosphorylated mTOR, Akt1,...
US20140194463 COMPOSITIONS FOR TREATMENT OF CANCER  
Compounds that are specifically toxic to cancer stem cells are disclosed.
US20140194429 COMPOSITIONS FOR TREATMENT OF CANCER  
Compounds that are specifically toxic to cancer stem cells are disclosed.
US20110207741 Activation of the Renin-Angiotensin System (RAS) and Sudden Cardiac Death  
Provided herein are methods of treating a medical condition in which RAS activation is increased. The method comprises the step of administering to a subject a c-Src inhibitor in an amount...
US20120046307 ALLOSTERIC PROTEIN KINASE MODULATORS  
The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein...
US20140045884 TREATMENT METHODS OF COGNITIVE, EMOTIONAL AND MENTAL AILMENTS AND DISORDERS  
Methods for the treatment of cognitive, emotional and mental ailments using therapeutically effective amounts of compositions including leukotriene receptor antagonists, leukotriene synthesis...
US20130217714 Non-Flushing Niacin Analogues, and Methods of Use Thereof  
One aspect of the present invention relates to substituted pyridines and pharmaceutically acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the...
US20150150273 ANTIMICROBIAL COMPOSITIONS WITHIN ANTIOXIDANT SOLUTIONS USED TO PROTECT WHOLE PROTEIN FOODS  
An antimicrobial composition within an antioxidant solution and used to protect whole protein food source is provided. The antimicrobial compound of the composition is selected preferably from a...
US20110288111 INHIBITION OF INFLUENZA M2 PROTON CHANNEL  
Provided are compounds that are capable of modulating the activity of the influenza A virus via interaction with the M2 transmembrane protein. Also provided are methods for treating an influenza...
US20120207766 INTRACELLULAR TOLL-LIKE RECEPTORS PATHWAYS AND AXONAL DEGENERATION  
The present invention is directed to the identification of novel mechanisms involved in the initiation and spreading of axonal degeneration. In particular, the instant invention relates to the...
US20140200241 PRODRUGS FOR TREATING MICROBIAL INFECTIONS  
Disclosed are methods of inhibiting the growth of pathogens using prodrug compounds as described herein. Also disclosed are methods of treating microbial infections using such compounds.
US20140303203 COMPOUNDS FOR TREATING PERIPHERAL; NEUROPATHIES AND OTHER NEURODEGENERATIVE; DISORDERS  
Compounds and methods for treating or preventing a neurodegenerative disease, disorder or condition associated with the overall activity of hsp90 but not with the ATPase activity of hsp90,...
US20120108630 Hedgehog Pathway Antagonists and Methods of Use  
The present disclosure provides for compounds, pharmaceutical preparations, kits and methods for the inhibition of the Hh pathway and the alleviation of cancer and developmental disorders...
US20110015201 HEDGEHOG PATHWAY ANTAGONISTS AND METHODS OF USE  
The present disclosure provides for compounds, pharmaceutical preparations, kits and methods for the inhibition of the Hh pathway and the alleviation of cancer and developmental disorders...
US20120022070 Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use  
Novel classes of molecular chaperone Heat shock protein 90 (Hsp90) inhibitors are disclosed. These compounds are useful in treating and preventing cancer and other Hsp90-related diseases and...
US20110172171 TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION OF BRAIN OEDEMA  
The present invention relates to taurine or taurine-like substances for the prevention of brain oedema, particularly brain intramyelinic oedema and more particularly brain intramyelinic oedema...
US20110301156 Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof to Treat Pain and Other Conditions  
Vanilloid receptor ligand compounds corresponding to formula I: pharmaceutical compositions containing such compounds, a process for producing such compounds, and methods of using such compounds...
US20100331330 METHODS AND COMPOSITIONS FOR TREATING ISCHEMIC STROKE  
A method of treating a cerebrovascular accident in a subject includes administering a therapeutically effective amount of at least one PPARγ agonist or a derivative thereof to the subject after...
US20070190188 Controlling Toxicity of Aminoquinoline Compounds  
A method of controlling toxicity to a user caused by administration to the user of an aminoquinoline compound comprising administering to the user a toxicity controlling amount of at least one...
US20110144155 8-HYDROXYQUINOLINE DERIVATIVES FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES  
The application relates to compositions and methods for treating hematological malignancies and proliferative diseases, disorders and conditions involving increased D-cyclin expression. In...
US20140235548 COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION  
Compounds, pharmaceutical compositions, and methods of using such compounds to treat or prevent diseases or disorders associated with or mediated by JAMM proteins are disclosed. The compounds and...
US20120149693 THERAPEUTIC COMPOUNDS  
The invention relates to protein binding interacting/binding compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for...
US20150126473 Ultra-Small ApoB-Containing Particles and Methods of Use Thereof  
The present disclosure provides an isolated particle comprising very high density, ultra small, lipid depleted apo B containing particles, and may also contain cytokeratin 8. The isolated particle...
US20110160236 Treating Vascular Events with Statins by Inhibiting PAR-1 and PAR-4  
The present invention relates to new methods for treating and/or preventing vascular events by inhibiting G-coupled Protease Activating Receptor (PAR)-1 and/or PAR-4 with the administration of...
US20120028933 Cell Culture Media Supplement and Method of Molecular Stress Control  
A novel class of agents has been identified to serve as cell-guard agents and/or target-specific supplements to increase cell quality and yield, as well as select for target cell populations....
US20110244045 CONTROLLED RELEASE OF N-ACETYLCYSTEINE (NAC) FOR REDUCTION OF SYSTEMIC AND/OR VASCULAR INFLAMMATION  
The present invention provides a controlled-release composition which provides a therapeutically effective plasma concentration of N-acetylcysteine over prolonged period of time. The present...
US20140155362 BHQ-CONJUGATES, AND RELATED COMPOUNDS, METHODS OF MAKING THE SAME, AND METHODS OF USE THEREOF  
Embodiments of the present disclosure provide for BHQ-conjugates and protected BHQ-conjugate precursor compounds, methods of making BHQ-conjugates and protected BHQ-conjugate precursor compounds,...
US20140044668 Methods for Predicting Cardiovascular Risks and Responsiveness to Statin Therapy Using SNPs  
Methods and compositions for the effect of Cholesteryl ester transfer protein (CETP) polymorphisms on mRNA splicing, statin treatment outcome, response to CETP inhibitor drugs, and myocardial...
US20110152315 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES  
There is provided novel compounds capable of modulating the G-protein-coupled receptor GPR40, compositions comprising the compounds, and methods for their use for controlling insulin levels in...
US20150196571 PROCESS AND COMPOSITION FOR STABILIZATION OF VULNERABLE PLAQUE UTILIZING A COMBINATION OF A STATIN AND OMEGA 3 FATTY ACIDS  
A composition and a method of treatment utilizing a combination of statins (or HMG-CoA reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA...
US20110251238 PPAR AGONIST COMPOSITIONS AND METHODS OF USE  
Method for treating or preventing a PPAR-responsive condition in a subject, comprising administering to the subject a PPAR agonist that comprises a 8-hydroxyquinoline-methylene-N- group in an...
US20060019932 Treatment of rheumatoid arthritis by inhibition of pde4  
A method of treatment of rheumatoid arthritis administers an effective amount of a compound that inhibits phospho-diesterase-4.
US20060194840 Method for treating snoring and sleep apnea with leukotriene antagonists  
A method of treating snoring and/or sleep apnea comprising administering to a patient in need of such treatment a therapeutically effective amount of a leukotriene receptor antagonist.
US20140335019 COMPOSITIONS AND METHODS FOR THE TREATMENT AND ANALYSIS OF NEUROLOGICAL DISORDERS  
Provided herein are compositions and methods for the treatment and analysis of neurological disorders. In particular, provided herein are small molecules targeted to amyloid-β (Aβ) or metal-Aβ...
US20100305056 CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASE  
Several parasites responsible for mammalian diseases are dependent on cysteine protease for various life-cycle functions. Inhibition or decreasing function of these proteases can be useful in the...
US20120232031 INJECTABLE FORMULATIONS FOR INTRA-ARTICULAR OR PERI-ARTICULAR ADMINISTRATION  
Described herein are injectable formulations for intra-articular or peri-articular administration, wherein the formulation is administered to treat joint pain. An injectable formulation for...
US20140087059 PHARMACEUTICAL COMPOSITION AND PROCESS FOR MONTELUKAST TABLETS  
The manufacture of compositions containing montelukast and to stable tablet compositions resulting thereof are disclosed, which include a first compaction step of a dry blend including,...
US20100179115 USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2  
The invention pertains to the discovery that type II glucocorticoid receptor antagonists can be used in methods for reversing or inhibiting the symptoms of depression in patients receiving...
US20120214824 PROTEOSTASIS REGULATORS  
The present invention is directed to compounds of Formulae (I), (II), (III), (IV), (V), (VI), (VII), and (VIII), pharmaceutical compositions thereof and methods of use thereof in the treatment of...
US20110039802 NPY Y5 ANTAGONIST  
The present invention provides a pharmaceutical composition for use as an NPY Y5 receptor antagonist comprising a compound of the formula (I): wherein R1 is lower alkyl, cycloalkyl or the like, R2...
US20150024032 METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA  
Embodiments of the invention include methods of treating, preventing, and/or reduce the risk or severity of a condition selected from the group consisting of muscle wasting, muscle weakness,...
US20150038530 COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MAST CELL-INDUCED VASCULAR LEAKAGE  
Disclosed herein are methods of diagnosing and treating infectious disease characterized by a pathology that involves hemorrhaging or pathological vascular leakage.
US20150105372 SECONDARY ALCOHOL QUINOLINYL MODULATORS OF RORyt  
The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or...
US20120035197 Novel Use of Fibrates  
The present invention, which is applicable in the pharmaceutical industry, relates to the use of fibrates, in particular fenofibrate, especially in the form of a solid oral composition, for the...
US20110065715 Nogo Receptor Binding Small Molecules to Promote Axonal Growth  
The present invention provides a method for identifying compounds which modulate the interaction of Nogo and Nogo receptor (NgR). The present invention also provides compounds that modulate the...
US20130005759 SMALL MOLECULE MODIFIERS OF MICRORNA MIR-122  
MicroRNAs are a class of endogenous regulators of gene function. Aberrant regulation of microRNAs has been linked to various human diseases, most importantly cancer. Small molecule intervention of...
US20150018371 POSITIVE ALLOSTERIC MODULATORS FOR MELANOCORTIN RECEPTORS  
Positive allosteric modulators of melanocortin receptors, especially allosteric potentiators of the receptors MC3R and MC4R are described herein. Also provided are pharmaceutical compositions...
US20060167045 Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin II type I receptor antagonist  
The present invention relates to the treatment of hypertension and type 2 diabetes, Metabolic Syndrome or a pre-diabetic state, by the administration of a therapeutically effective amount of a...
US20150086624 MULTILAYER COATING FORM OF ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION CONTAINING OMEGA-3 FATTY ACID OR ALKYL ESTER THEREOF AND STATIN BASED DRUG  
A pharmaceutical composition in multilayer-coated form including an omega-3 fatty acid or an alkyl ester thereof and a statin-based drug, and more particularly, a pharmaceutical composition for...